NEW YORK (GenomeWeb News) – Gene editing firm Editas Medicine today announced it has secured $43 million in Series A financing.

The financing was led by Flagship Ventures, Polaris Partners, and Third Rock Ventures. Partners Innovation Fund also participated.

Editas plans to use its genome editing technology to develop new therapeutics “that enable precise and corrective molecular modification to treat the underlying cause of a broad range of diseases at the genetic level.”

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

New Mexico is re-doing its proposed science education standards after criticism, the Associated Press reports.

Agbio executives say gene editing will speed up breeding efforts, according to the Wall Street Journal.

La Trobe University's Jenny Graves has won the $250,000 Prime Minister's Prize for Science, the Guardian reports.

In Cell this week: post-treatment changes to melanoma genome, multi-omics analysis of muscle-invasive bladder cancer, and more.